|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
|
|
OMB Number: 3235-0058
Expires: June 30, 2012
Estimated average burden
hours per response . . . . . . . 2.50
|
|
|
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
SEC FILE NUMBER
001-34808
|
|
|
CUSIP NUMBER
|
|
(Check one):
|
¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR
|
|
|
¨ Form N-CSR
|
|
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
|
If the notification relates to a portion of the filing checked above identify the Item(s) to which the notification relates:
|
|
China Botanic Pharmaceutical Inc.
|
|
Full Name of Registrant
|
|
Former Name if Applicable
|
|
Level 11, Changjiang International Building, No. 28, Changjiang Road, Nangang District, Harbin
|
|
Address of Principal Executive Office (Street and Number)
|
|
Heilongjiang Province, China 150090
|
|
City, State and Zip Code
|
|
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
|
|
x
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
|
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.
|
|
(1)
|
Name and telephone number of person to contact in regard to this notification.
|
|||||
|
Weiqiu Dong
|
86
|
451 5768 0200
|
||||
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
||||
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
|||||
|
Yes x No ¨
|
||||||
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|||||
|
Yes ¨ No x
|
||||||
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
||||||
|
China Botanic Pharmaceutical Inc.
|
|
(Name of Registrant as specified in its charter)
|
|
Date:
|
June 14, 2012
|
By:
|
/s/ Weiqiu Dong
|
|
|
Weiqiu Dong, Chief Financial Officer
|